Comment: Is 3,4-DAP a new option in treating MuSK MG?
Publication
, Journal Article
Hobson-Webb, LD
Published in: Neurology
March 15, 2016
Duke Scholars
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
March 15, 2016
Volume
86
Issue
11
Start / End Page
1071
Location
United States
Related Subject Headings
- Receptors, Cholinergic
- Receptor Protein-Tyrosine Kinases
- Neurology & Neurosurgery
- Myasthenia Gravis
- Humans
- Female
- Autoantibodies
- 4-Aminopyridine
- 3209 Neurosciences
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hobson-Webb, L. D. (2016). Comment: Is 3,4-DAP a new option in treating MuSK MG? Neurology, 86(11), 1071. https://doi.org/10.1212/WNL.0000000000002475
Hobson-Webb, Lisa D. “Comment: Is 3,4-DAP a new option in treating MuSK MG?” Neurology 86, no. 11 (March 15, 2016): 1071. https://doi.org/10.1212/WNL.0000000000002475.
Hobson-Webb LD. Comment: Is 3,4-DAP a new option in treating MuSK MG? Neurology. 2016 Mar 15;86(11):1071.
Hobson-Webb, Lisa D. “Comment: Is 3,4-DAP a new option in treating MuSK MG?” Neurology, vol. 86, no. 11, Mar. 2016, p. 1071. Pubmed, doi:10.1212/WNL.0000000000002475.
Hobson-Webb LD. Comment: Is 3,4-DAP a new option in treating MuSK MG? Neurology. 2016 Mar 15;86(11):1071.
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
March 15, 2016
Volume
86
Issue
11
Start / End Page
1071
Location
United States
Related Subject Headings
- Receptors, Cholinergic
- Receptor Protein-Tyrosine Kinases
- Neurology & Neurosurgery
- Myasthenia Gravis
- Humans
- Female
- Autoantibodies
- 4-Aminopyridine
- 3209 Neurosciences
- 3202 Clinical sciences